Pharma Equity Group

0.08 DKK

-4.55 %

Less than 1K followers

PEG

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

-4.55 %
-5.45 %
-27.12 %
-14.56 %
-19.39 %
+1.01 %
-79.85 %
-77.36 %
-99.69 %

Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.

Read more
Market cap
97.96M DKK
Turnover
130.32K DKK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Coverage
Disclaimer
Latest research

Latest analysis report

Released: 2026-04-08

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14/8
2026

Interim report Q2'26

ShowingAll content types
Pharma Equity Group (PEG): Set to secure European patent for IBD program
Analyst Comment by
Michael Friis

Pharma Equity Group (PEG): Set to secure European patent for IBD program

PEG announced this morning that its subsidiary Reponex Pharmaceuticals has received a notification from the European Patent Office (EPO) of its intention to grant a European patent covering compositions and methods for the treatment of Inflammatory Bowel Disease (IBD).Strategically, the patent grant supports PEG's broader narrative of gradually de-risking its repositioning-based pipeline through a combination of clinical, commercial, and IP-related milestones

Pharma Equity Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Pharma Equity Group (Investment case): Partnerships key to de-risk the investment case
Research by
Michael Friis

Pharma Equity Group (Investment case): Partnerships key to de-risk the investment case

In connection with the publication of Pharma Equity Group's annual report for 2025, 2026 guidance and ongoing clinical developments, we have published our investment case. Our investment case covers the key investment reasons and risks and valuation perspectives. PEG's investment case centres on de-risking its pipeline through clinical progress and strategic partnerships, while diversifying into revenue-generating assets through its expanded Life Science consolidator strategy. The drug repositioning approach — repurposing previously approved active pharmaceutical ingredients for new therapeutic applications — aims to reduce clinical risk relative to de novo drug development, and the out-licensing model post-Phase II is designed to limit capital requirements and execution risk.

Pharma Equity Group
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.